Elo Mutual Pension Insurance Co Acquires New Stake in Lantheus Holdings, Inc. $LNTH

Elo Mutual Pension Insurance Co bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 18,370 shares of the medical equipment provider’s stock, valued at approximately $942,000.

A number of other large investors have also modified their holdings of the business. Elevation Point Wealth Partners LLC purchased a new position in shares of Lantheus in the second quarter worth about $26,000. Osterweis Capital Management Inc. acquired a new stake in Lantheus in the 2nd quarter valued at about $36,000. Hantz Financial Services Inc. lifted its stake in Lantheus by 412.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 396 shares in the last quarter. First Horizon Corp acquired a new position in shares of Lantheus during the 3rd quarter worth approximately $26,000. Finally, EverSource Wealth Advisors LLC grew its position in shares of Lantheus by 190.2% in the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after purchasing an additional 698 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

LNTH has been the topic of a number of recent research reports. Truist Financial boosted their price objective on Lantheus from $82.00 to $89.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. JonesTrading cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. Citigroup reissued an “outperform” rating on shares of Lantheus in a report on Tuesday, February 24th. Citizens Jmp raised their price objective on shares of Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a research report on Tuesday, February 24th. Finally, William Blair upgraded shares of Lantheus from a “market perform” rating to an “outperform” rating in a report on Thursday, February 26th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $82.17.

Lantheus Stock Down 2.0%

Shares of LNTH opened at $76.31 on Friday. The company’s 50-day moving average price is $68.99 and its 200 day moving average price is $60.79. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $111.29. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52. The firm has a market cap of $4.93 billion, a P/E ratio of 22.64 and a beta of -0.11.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.50. The business had revenue of $406.79 million during the quarter, compared to analysts’ expectations of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The business’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same period last year, the business earned $1.59 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.